Compounds > cudraflavone c
Page last updated: 2024-12-11

cudraflavone c

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cudraflavone C: a tyrosinase inhibitor with antimicrobial activity; isolated from Artocarpus integer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cudraflavone C : A tetrahydroxyflavone that is flavone substituted by hydroxy groups at positions 5, 7, 2' and 4' and prenyl groups at positions 3 and 6. Isolated from Morus nigra, it exhibits antibacterial and cytotoxic activities. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
MorusgenusA plant genus of the family MORACEAE that is widely planted for shade.[MeSH]MoraceaeThe mulberry plant family of the order Urticales, subclass Hamamelidae, class Magnoliopsida. They have milky latex and small, petalless male or female flowers.[MeSH]
ArtocarpusgenusA plant genus of the family MORACEAE. Puag-haad extract, from A. lakoocha, contains STILBENES and related 4-substituted RESORCINOLS.[MeSH]MoraceaeThe mulberry plant family of the order Urticales, subclass Hamamelidae, class Magnoliopsida. They have milky latex and small, petalless male or female flowers.[MeSH]
Morus nigraspecies[no description available]MoraceaeThe mulberry plant family of the order Urticales, subclass Hamamelidae, class Magnoliopsida. They have milky latex and small, petalless male or female flowers.[MeSH]

Cross-References

ID SourceID
PubMed CID5319924
CHEMBL ID485777
CHEBI ID68023
MeSH IDM000603188

Synonyms (15)

Synonym
cudraflavone c
4h-1-benzopyran-4-one, 2-(2,4-dihydroxy-phenyl)-5,7-dihydroxy-3,6-bis(3-methyl-2-butenyl)-
19275-47-9
2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-3,6-bis(3-methylbut-2-enyl)chromen-4-one
nsc720089
nsc-720089
CHEMBL485777
chebi:68023 ,
2',4',5,7-tetrahydroxy-3,6-bis(3-methyl-2-butenyl)flavone
LMPK12110902
bdbm50291327
2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-3,6-bis(3-methylbut-2-en-1-yl)-4h-chromen-4-one
2-(2,4-dihydroxy-phenyl)-5,7-dihydroxy-3,6-bis(3-methyl-2-butenyl)-4h-1-benzopyran-4-one
DTXSID80172870
Q27136508

Research Excerpts

Overview

Cudraflavone C (Cud C) is a naturally-occurring flavonol with reported anti-proliferative activities.

ExcerptReferenceRelevance
"Cudraflavone C (Cud C) is a naturally-occurring flavonol with reported anti-proliferative activities. "( Cudraflavone C Induces Tumor-Specific Apoptosis in Colorectal Cancer Cells through Inhibition of the Phosphoinositide 3-Kinase (PI3K)-AKT Pathway.
Bradshaw, TD; Chung, FF; Hii, LW; Leong, CO; Lim, KH; Mai, CW; See, SJ; Soo, HC; Tan, SH; Tan, YF; Yap, VA, 2017)		3.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antibacterial agentA substance (or active part thereof) that kills or slows the growth of bacteria.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
tetrahydroxyflavoneAny hydroxyflavone carrying four hydroxy substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)IC50 (µMol)0.26000.00001.146310.0000AID1351564
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (18)

Processvia Protein(s)Taxonomy
regulation of heart ratecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cAMP catabolic processcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of heart ratecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulumcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of type II interferon productioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of interleukin-2 productioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of interleukin-5 productioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of peptidyl-serine phosphorylationcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of heart contractioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
T cell receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
establishment of endothelial barriercAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
adrenergic receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of cardiac muscle cell contractioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of cell communication by electrical coupling involved in cardiac conductioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of relaxation of cardiac musclecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channelcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cAMP-mediated signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
3',5'-cyclic-nucleotide phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
calcium channel regulator activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
enzyme bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
signaling receptor regulator activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cAMP bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
beta-2 adrenergic receptor bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
transmembrane transporter bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
metal ion bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
ATPase bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
scaffold protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
heterocyclic compound bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
centrosomecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
plasma membranecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
apical plasma membranecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
voltage-gated calcium channel complexcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
calcium channel complexcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
nucleuscAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (69)

Assay IDTitleYearJournalArticle
AID1781753Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as fractional inhibitory concentration in presence of daptomycin incubated for 24 hrs by checkerboard assay
AID376640Selectivity index, ratio of CC50 for mouse RAW264.7 cells to IC50 for nitric oxide production in mouse RAW264.7 cells2006Journal of natural products, Apr, Volume: 69, Issue:4
Prenylated flavonoids from the heartwood of Artocarpus communis with inhibitory activity on lipopolysaccharide-induced nitric oxide production.
AID596763Induction of mouse 3T3L1 cell differentiation assessed as increase in accumulation of intracellular lipid droplet at 25 uM by Oil red O staining2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Isoprenylated flavonoids and adipogenesis-promoting constituents from Morus nigra.
AID1781738Antibacterial activity against vancomycin-resistant Staphylococcus aureus VRS4 assessed as bacterial growth inhibition incubated for 16 to 18 hrs by broth microdilution method
AID1781732Antibacterial activity against methicillin-resistant Staphylococcus aureus NRS 10192 assessed as bacterial growth inhibition incubated for 16 to 18 hrs by broth microdilution method
AID1781739Antibacterial activity against vancomycin-resistant Staphylococcus aureus VRS12 assessed as bacterial growth inhibition incubated for 16 to 18 hrs by broth microdilution method
AID1781748Bactericidal activity against Staphylococcus aureus ATCC 29213 assessed as reduction in bacterial load at 1X MIC preincubated for 6 hrs followed by subculturing on TSA plate for 18 to 20 hrs by time-kill assay
AID1781757Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as fractional inhibitory concentration in presence of meropenem incubated for 24 hrs by checkerboard assay
AID1781725Selectivity index, ratio of CC50 for cytotoxicity against African green monkey Vero cells to MIC for antibacterial activity against Staphylococcus aureus ATCC 29213
AID1781746Antibacterial activity against vancomycin-resistant Enterococcus NR 31909 assessed as bacterial growth inhibition incubated for 16 to 18 hrs by broth microdilution method
AID1781775Synergistic bactericidal activity against Staphylococcus aureus ATCC 29213 assessed as reduction in bacterial load at 1X MIC preincubated for 6 hrs in presence of gentamycin followed by subculturing on TSA plate for 18 to 20 hrs by time-kill assay
AID1781719Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as bacterial growth inhibition incubated for 16 to 18 hrs by broth microdilution method
AID696879Inhibition of tyrosinase using L-dihydroxyphenylalanine as substrate preincubated for 30 mins measured after 7 mins by spectrophotometric analysis2012Journal of natural products, Nov-26, Volume: 75, Issue:11
Tyrosinase inhibitors from the wood of Artocarpus heterophyllus.
AID1781722Antibacterial activity against Klebsiella pneumoniae BAA-1705 assessed as bacterial growth inhibition incubated for 16 to 18 hrs by broth microdilution method
AID1781756Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as fractional inhibitory concentration in presence of linezolid incubated for 24 hrs by checkerboard assay
AID1781743Antibacterial activity against vancomycin-susceptible Enterococcus NR 31887 assessed as bacterial growth inhibition incubated for 16 to 18 hrs by broth microdilution method
AID1781751Antibacterial activity against Staphylococcus aureus ATCC 29213 infected in mouse J774.A1 assessed as reduction in intracellular bacterial burden at 5XMIC incubated for 24 hrs followed by replating on TSA plate for 24 hrs by intracellular killing assay
AID1781755Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as fractional inhibitory concentration in presence of levofloxacin incubated for 24 hrs by checkerboard assay
AID1781733Antibacterial activity against methicillin-resistant Staphylococcus aureus NRS 10191 assessed as bacterial growth inhibition incubated for 16 to 18 hrs by broth microdilution method
AID1781769Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as bacterial growth inhibition in presence of levofloxacin incubated for 24 hrs by checkerboard assay
AID1781718Cytotoxicity against African green monkey Vero cells incubated for 72 hrs by MTT assay
AID1781758Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as fractional inhibitory concentration in presence of minocycline incubated for 24 hrs by checkerboard assay
AID376638Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells assessed as nitrite accumulation after 20 hrs2006Journal of natural products, Apr, Volume: 69, Issue:4
Prenylated flavonoids from the heartwood of Artocarpus communis with inhibitory activity on lipopolysaccharide-induced nitric oxide production.
AID378244Cytotoxicity against human CEM-SS cells2000Journal of natural products, Nov, Volume: 63, Issue:11
HIV-Inhibitory prenylated xanthones and flavones from Maclura tinctoria.
AID1781762Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as reduction in bacterial growth at sub-MIC incubated for more than 40 days
AID1781774Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as bacterial growth inhibition in presence of vancomycin incubated for 24 hrs by checkerboard assay
AID1781745Antibacterial activity against vancomycin-resistant Enterococcus NR 31903 assessed as bacterial growth inhibition incubated for 16 to 18 hrs by broth microdilution method
AID1781760Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as fractional inhibitory concentration in presence of vancomycin incubated for 24 hrs by checkerboard assay
AID1781740Antibacterial activity against vancomycin-susceptible Enterococcus NR 31884 assessed as bacterial growth inhibition incubated for 16 to 18 hrs by broth microdilution method
AID1781735Antibacterial activity against methicillin-resistant Staphylococcus aureus NRS 10186 assessed as bacterial growth inhibition incubated for 16 to 18 hrs by broth microdilution method
AID1781744Antibacterial activity against vancomycin-susceptible Enterococcus NR 31888 assessed as bacterial growth inhibition incubated for 16 to 18 hrs by broth microdilution method
AID1781761Synergistic antibacterial activity against multidrug-resistant methicillin resistant Staphylococcus aureus NRS 10119 assessed as reduction in bacterial load at 1X MIC preincubated for 24 hrs in presence of gentamycin followed by subculturing on TSA plate
AID1781728Antibacterial activity against methicillin-resistant Staphylococcus aureus NRS 10119 assessed as bacterial growth inhibition incubated for 16 to 18 hrs by broth microdilution method
AID1781726Antibacterial activity against Escherichia coli ATCC 25922 assessed as bacterial growth inhibition in presence of outermembrane permeabilizer, PMBN incubated for 16 to 18 hrs by broth microdilution method
AID1781767Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as bacterial growth inhibition in presence of daptomycin incubated for 24 hrs by checkerboard assay
AID1781737Antibacterial activity against vancomycin-resistant Staphylococcus aureus VRS1 assessed as bacterial growth inhibition incubated for 16 to 18 hrs by broth microdilution method
AID378243Antiviral activity against HIV12000Journal of natural products, Nov, Volume: 63, Issue:11
HIV-Inhibitory prenylated xanthones and flavones from Maclura tinctoria.
AID1781730Antibacterial activity against methicillin-resistant Staphylococcus aureus NRS 10129 assessed as bacterial growth inhibition incubated for 16 to 18 hrs by broth microdilution method
AID1781720Antibacterial activity against Escherichia coli ATCC 25922 assessed as bacterial growth inhibition incubated for 16 to 18 hrs by broth microdilution method
AID1781773Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as bacterial growth inhibition in presence of rifampicin incubated for 24 hrs by checkerboard assay
AID1781766Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as bacterial growth inhibition in presence of ceftazidime incubated for 24 hrs by checkerboard assay
AID1781754Synergistic antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as fractional inhibitory concentration in presence of gentamycin incubated for 24 hrs by checkerboard assay
AID1781749Antibiofilm activity against Staphylococcus aureus ATCC 29213 assessed as reduction in preformed bacterial biofilm at 1XMIC incubated for 24 hrs by crystal violet staining based microtiter plate reader assay
AID1781727Antibacterial activity against Acinetobacter baumannii BAA-1605 ssessed as bacterial growth inhibition in presence of outermembrane permeabilizer, PMBN incubated for 16 to 18 hrs by broth microdilution method
AID1781724Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as bacterial growth inhibition incubated for 16 to 18 hrs by broth microdilution method
AID1781721Antibacterial activity against Acinetobacter baumannii BAA 1605 assessed as bacterial growth inhibition incubated for 16 to 18 hrs by broth microdilution method
AID1781768Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as bacterial growth inhibition in presence of gentamycin incubated for 24 hrs by checkerboard assay
AID1781723Antibacterial activity against Enterococcus NR 31884 assessed as bacterial growth inhibition incubated for 16 to 18 hrs by broth microdilution method
AID1781731Antibacterial activity against methicillin-resistant Staphylococcus aureus NRS 10198 assessed as bacterial growth inhibition incubated for 16 to 18 hrs by broth microdilution method
AID1781736Antibacterial activity against methicillin-resistant Staphylococcus aureus NRS 10194 assessed as bacterial growth inhibition incubated for 16 to 18 hrs by broth microdilution method
AID1781747Antibacterial activity against vancomycin-resistant Enterococcus NR 31912 assessed as bacterial growth inhibition incubated for 16 to 18 hrs by broth microdilution method
AID1781734Antibacterial activity against methicillin-resistant Staphylococcus aureus NRS 10193 assessed as bacterial growth inhibition incubated for 16 to 18 hrs by broth microdilution method
AID1781779Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as time for post-antibiotic effect at 10XMIC incubated for 1 hr followed by drug wash-out and measured every single 1 hr
AID1781764Bactericidal activity against Staphylococcus aureus ATCC 29213 assessed as reduction in bacterial load at 10X MIC preincubated for 1 hr followed by subculturing on TSA plate for 18 to 20 hrs by time-kill assay
AID1781777Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as time for increase by 1 log10CFU at 10XMIC incubated for 1 hr followed by drug wash-out and measured every single 1 hr
AID1781741Antibacterial activity against vancomycin-susceptible Enterococcus NR 31885 assessed as bacterial growth inhibition incubated for 16 to 18 hrs by broth microdilution method
AID1781763Bactericidal activity against Staphylococcus aureus ATCC 29213 assessed as reduction in bacterial load at 10X MIC preincubated for 6 hrs followed by subculturing on TSA plate for 18 to 20 hrs by time-kill assay
AID1781742Antibacterial activity against vancomycin-susceptible Enterococcus NR 31886 assessed as bacterial growth inhibition incubated for 16 to 18 hrs by broth microdilution method
AID1781772Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as bacterial growth inhibition in presence of minocycline incubated for 24 hrs by checkerboard assay
AID1781771Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as bacterial growth inhibition in presence of meropenem incubated for 24 hrs by checkerboard assay
AID1781759Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as fractional inhibitory concentration in presence of rifampicin incubated for 24 hrs by checkerboard assay
AID376639Cytotoxicity against mouse RAW264.7 cells by MTT assay2006Journal of natural products, Apr, Volume: 69, Issue:4
Prenylated flavonoids from the heartwood of Artocarpus communis with inhibitory activity on lipopolysaccharide-induced nitric oxide production.
AID1781776Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as time for increase by 1 log10CFU at 1XMIC incubated for 1 hr followed by drug wash-out and measured every single 1 hr
AID1781729Antibacterial activity against methicillin-resistant Staphylococcus aureus NRS 10100 assessed as bacterial growth inhibition incubated for 16 to 18 hrs by broth microdilution method
AID1781750Antibiofilm activity against Staphylococcus aureus ATCC 29213 assessed as reduction in preformed bacterial biofilm at 10XMIC incubated for 24 hrs by crystal violet staining based microtiter plate reader assay
AID1781752Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as fractional inhibitory concentration in presence of ceftazidime incubated for 24 hrs by checkerboard assay
AID1351564Inhibition of human PDE4D2 catalytic domain (86 to 413 residues) expressed in Escherichia coli strain BL21 using [3H]cAMP as substrate after 15 mins by liquid scintillation counter analysis2018European journal of medicinal chemistry, Jan-20, Volume: 144Prenylated flavonoids as potent phosphodiesterase-4 inhibitors from Morus alba: Isolation, modification, and structure-activity relationship study.
AID1781778Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as time for post-antibiotic effect at 1XMIC incubated for 1 hr followed by drug wash-out and measured every single 1 hr
AID1781770Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as bacterial growth inhibition in presence of linezolid incubated for 24 hrs by checkerboard assay
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (22.22)29.6817
2010's6 (66.67)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.03

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.03 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index5.33 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.03)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
4-hydroxybenzoic acid
4-hydroxybenzoic acid : A monohydroxybenzoic acid that is benzoic acid carrying a hydroxy substituent at C-4 of the benzene ring.		2.0710monohydroxybenzoic acidalgal metabolite;
plant metabolite
beta-resorcylic acid
beta-resorcylic acid: RN given refers to parent cpd; structure		2.0710
kojic acid
[no description available]		2.07104-pyranones;
enol;
primary alcohol		Aspergillus metabolite;
EC 1.10.3.1 (catechol oxidase) inhibitor;
EC 1.10.3.2 (laccase) inhibitor;
EC 1.13.11.24 (quercetin 2,3-dioxygenase) inhibitor;
EC 1.14.18.1 (tyrosinase) inhibitor;
EC 1.4.3.3 (D-amino-acid oxidase) inhibitor;
NF-kappaB inhibitor;
skin lightening agent
rolipram
[no description available]		2.1710pyrrolidin-2-onesantidepressant;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
vanillic acid
Vanillic Acid: A flavoring agent. It is the intermediate product in the two-step bioconversion of ferulic acid to vanillin. (J Biotechnol 1996;50(2-3):107-13).. vanillic acid : A monohydroxybenzoic acid that is 4-hydroxybenzoic acid substituted by a methoxy group at position 3.		2.0710methoxybenzoic acid;
monohydroxybenzoic acid		plant metabolite
rosiglitazone
[no description available]		2.0610aminopyridine;
thiazolidinediones		EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
insulin-sensitizing drug
omega-n-methylarginine
omega-N-Methylarginine: A competitive inhibitor of nitric oxide synthetase.. N(omega)-methyl-L-arginine : A L-arginine derivative with a N(omega)-methyl substituent.		2.0310amino acid zwitterion;
arginine derivative;
guanidines;
L-arginine derivative;
non-proteinogenic L-alpha-amino acid
8-deoxygartanin
8-deoxygartanin: a butyrylcholinesterase inhibitor; isolated from Garcinia mangostana; structure in first source		210xanthones
8-isopentenylnaringenin
8-isopentenylnaringenin: a non-steroidal phytoestrogen from Anaxagorea luzonensis; structure in first source		2.0310flavanones
trans-4-coumaric acid
hydroxycinnamic acid : Any member of the class of cinnamic acids carrying one or more hydroxy substituents.. trans-4-coumaric acid : The trans-isomer of 4-coumaric acid.. 4-coumaric acid : A coumaric acid in which the hydroxy substituent is located at C-4 of the phenyl ring.		2.07104-coumaric acidfood component;
mouse metabolite;
plant metabolite
isobavachalcone
isobavachalcone: RN given for (E)-isomer; structure in first source. isobavachalcone : A member of the class of chalcones that is trans-chalcone substituted by hydroxy groups at positions 4, 2' and 4' and a prenyl group at position 3'.		2.0310chalcones;
polyphenol		antibacterial agent;
metabolite;
platelet aggregation inhibitor
gartanin
gartanin : A member of the class of xanthones that is 9H-xanthen-9-one substituted by hydroxy groups at positions 1, 3, 5 and 8 and prenyl groups at positions 2 and 4.		210polyphenol;
xanthones		antineoplastic agent;
plant metabolite
morusin
morusin: from Morus root bark; structure given in first source. morusin : An extended flavonoid that is flavone substituted by hydroxy groups at positions 5, 2' and 4', a prenyl group at position 3 and a 2,2-dimethyl pyran group across positions 7 and 8.		2.1710extended flavonoid;
trihydroxyflavone		antineoplastic agent;
plant metabolite
Cudraflavone A
[no description available]		2.0310extended flavonoid
macluraxanthone b
macluraxanthone B: from the plant Maclura tinctoria; structure in first source. macluraxanthone B : A member of the class of xanthones that is 9H-xanthen-9-one substituted by hydroxy groups at positions 1, 3, 6 and 7, a dimethylallyl group at position 2 and a prenyl group at position 4. Isolated from Maclura tinctoria and Cudrania tricuspidata, it exhibits anti-HIV and antineoplastic activity.		210phenols;
xanthones		anti-HIV agent;
antineoplastic agent;
metabolite
artocarpin lectin
artocarpin lectin: a mannose-specific lectin; from the seeds of Artocarpus integrifolia; a homotetramic protein distinct from jacalin, another jackfruit lectin; MW 65 kDa; devoid of covalently-attached carbohydrates; consists of 4 isolectins with pI 5 - 6.5; do not confuse with artocarpin flavone. artocarpin : A trihydroxyflavone that is flavone substituted by hydroxy groups at positions 5, 2', and 4', a methoxy group at position 7, a prenyl group at position 3 and a (1E)-3-methylbut-1-enyl group at position 6. Isolated from Artocarpus heterophyllus and Artocarpus integrifolia, it exhibits antineoplastic activity.		2.4620monomethoxyflavone;
trihydroxyflavone		antineoplastic agent;
metabolite
morachalcone a
morachalcone A: tyrosinase inhibitor from the wood of Artocarpus heterophyllus; structure in first source		2.4520chalcones
licoflavone c
licoflavone C: Antimutagenic Agent; a naturally occurring prenyl-flavone extracted from Genista ephedroides; structure in first source		2.1710
artocarpanone
artocarpanone: from Artocarpus heterophyllus; structure in first source		2.110
ConditionIndicatedRelationship StrengthStudiesTrials
HIV
Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.		0210
Malignant Melanoma
[description not available]		02.1510
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		07.1510
Colorectal Cancer
[description not available]		07.1510
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		02.1510